Navigation Links
Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence
Date:9/23/2008

Study Shows near 80% Improvement In Outcomes

PITTSBURGH, Sept. 23 /PRNewswire/ -- Radiation oncologists at Allegheny General Hospital (AGH) in Pittsburgh today will report to the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston that a newer, minimally invasive approach to treating high risk patients with Stage I non-small cell lung carcinoma (NSCLC) may significantly reduce the risk of local disease recurrence.

Developed at AGH over the past decade, the procedure involves removing only the cancerous section of the lung and enveloping the surgical site in a mesh material that is embedded with radioactive seeds. The seeds emit a low dose of radiation over a prolonged period of time in an effort to eradicate any remaining cancer cells.

Lung cancer is the leading cause of cancer death in the United States. Non-small cell lung carcinoma is the most common form of the disease, accounting for an estimated 85% of all cases. Stage I NSCLC is characterized by disease that is localized in the lung with no metastasis to the lymph node system.

"The standard of care for patients with this particular disease is a lobectomy, or surgical removal of the entire lobe of the lung. Many patients, however, are considered high risk for this procedure due to cardiopulmonary complications or other co-morbidities. In these cases, sublobar wedge resection is a more tolerable approach, but one that carries a much higher chance of local cancer recurrence," said Athanasios Colonias, MD, an AGH radiation oncologist and the study's principal investigator.

"Our study suggests that when intraoperative 125I Vicryl(R) mesh brachytherapy is added to sublobar resection, the local treatment failure rate is substantially reduced," Dr. Colonias said.

Dr. Colonias and his AGH colleagues examined the outcomes of 145 high-risk patients with Stage I NSCLC who underwent sublobar resection (SLR) with adjuvant intraoperative mesh brachytherapy between January 1996 to February 2008. Local treatment failure was defined as a cancer recurrence within the involved lobe.

At a median follow-up of 38 months, the AGH team documented just six local recurrences (4.1%) with the group, compared to an expected cancer recurrence rate of 20% with SLR only based on previously published data. No patient/tumor specific factors (age, histology, gender, stage, location of tumor, tumor size) or surgical/dosimetric factors (margin status, open vs. video assisted approach, total activity, number of seeds, dose prescribed, target area) were predictive of local recurrence. All of the procedures were well tolerated by patients with regard to pulmonary function and morbidity.

"Of the more than 150,000 people diagnosed each year with lung cancer, less than 20% are identified with disease in its earliest and most curable stage. For high risk patients, however, even a Stage I diagnosis poses significant therapeutic challenges and generally poor odds of a long-term recovery. It would appear that those odds may be improved considerably by combining sublobar resection with intraoperative mesh brachytherapy," said Robert Keenan, M.D., director of AGH's Center for Thoracic Surgery.

Dr. Keenan said a large, randomized multi-center clinical trial of SLR +/- brachytherapy is currently underway and will more definitively establish the efficacy of the procedure. The study is being coordinated by the American College of Surgeons Oncology Group and involves more than a dozen major U.S. Hospitals, including AGH.


'/>"/>
SOURCE Allegheny General Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Astro Meeting
2. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
3. Breast MRI Scan Could Determine Need for Radiation Therapy
4. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
7. St. Jude Study Finds Treatment With New Drug Might Make Tumor Cells More Sensitive to Therapy
8. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
9. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
10. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
11. New Research Shows Physical Therapy as Effective as Arthroscopic Knee Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016   Acsis , a leading provider of ... market research and advisory firm IDC has named it ... Worldwide Pharmaceutical Track and Trace Software 2016 Vendor Assessment ... assessment of the capabilities and business strategies of 10 ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating its ... location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There ... TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, DDS, ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility ... the armpits, the M+D Crutch evenly distributes body weight from the elbow to the ... when using the crutches than with other crutches. , Co-founders Max and Liliana Younger ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
Breaking Medicine News(10 mins):